Innate Pharma (IPHA) Receivables (2017 - 2025)

Innate Pharma (IPHA) has reported Receivables for 9 consecutive years, with $14.5 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables fell 11.27% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 11.27% YoY) and the FY2025 annual result came in at $15.0 million, down 8.15% from the prior year.
• Receivables declined to $14.5 million in Q4 2025 per IPHA's latest filing, from $19.7 million in the prior quarter.
• Over the last five years, Receivables for IPHA reached as high as $76.5 million in Q2 2022 and fell as low as $14.5 million in Q4 2025.
• A 5-year average of $43.0 million and a median of $46.4 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2021 — Receivables tumbled 99.67% — and 2022, when it soared 172.99%.
• Year by year, Receivables stood at $21.9 million in 2021, then surged by 172.99% to $59.7 million in 2022, then grew by 6.01% to $63.3 million in 2023, then tumbled by 74.15% to $16.4 million in 2024, then retreated by 11.27% to $14.5 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $14.5 million, $19.7 million, and $16.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.